(0.41%) 5 112.50 points
(0.81%) 38 691 points
(0.70%) 17 774 points
(0.19%) $79.10
(-0.10%) $2.03
(-0.04%) $2 308.70
(-0.16%) $26.79
(1.45%) $976.60
(-0.12%) $0.931
(-0.64%) $10.92
(-0.17%) $0.797
(0.50%) $91.58
-84.62% $ 0.000200
Live Chart Being Loaded With Signals
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'...
Stats | |
---|---|
Dagens volum | 2.06M |
Gjennomsnittsvolum | 341 846 |
Markedsverdi | 23 816.00 |
EPS | $0 ( 2024-03-28 ) |
Neste inntjeningsdato | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.000392 |
ATR14 | $0.00100 (1 000.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-18 | Chappell Dale | Sell | 276 210 | Common Stock, $0.001 par value |
2023-10-18 | Chappell Dale | Sell | 75 887 | Common Stock, $0.001 par value |
2023-10-18 | Chappell Dale | Sell | 34 253 | Common Stock, $0.001 par value |
2022-07-27 | Buxton Cheryl | Buy | 78 362 | Stock Option (Right to Buy) |
2022-07-27 | Hohneker John | Buy | 63 195 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
36.18 |
Last 98 transactions |
Buy: 5 830 886 | Sell: 2 957 610 |
Volum Korrelasjon
Humanigen, Inc. Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Humanigen, Inc. Korrelasjon - Valuta/Råvare
Humanigen, Inc. Økonomi
Annual | 2022 |
Omsetning: | $2.51M |
Bruttogevinst: | $2.51M (100.00 %) |
EPS: | $-1.180 |
FY | 2022 |
Omsetning: | $2.51M |
Bruttogevinst: | $2.51M (100.00 %) |
EPS: | $-1.180 |
FY | 2021 |
Omsetning: | $3.60M |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-3.98 |
FY | 2020 |
Omsetning: | $312 000 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-2.42 |
Financial Reports:
No articles found.
Humanigen, Inc.
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.